首页>投融资
NRx Pharmaceuticals
增发
NRX Pharmaceuticals, Inc.是于2015年5月20日依照特拉华州法律成立的公司,是一家临床阶段的小分子制药公司,开发用于治疗中枢神经系统疾病和危及生命的肺部疾病的新型疗法。
基本信息
-
公司全称NRx Pharmaceuticals Inc
-
类型生物药开发商
-
产业领域药品研发/制造、生物药、化学药
-
公司人数15人以下
-
地址1201 Orange Street Suite 600 WILMINGTON DELAWARE 19801; US; Telephone: +14842546134;
-
联系电话1-484-2546134
-
邮箱rackerman@bigrockpartners.com
-
成立时间2015-01-01
投融资
-
2023-06-09增发628万美元未透露
-
2023-03-09增发290万美元未透露
-
2022-11-07IPO后其他轮次1100万美元Streeterville Capital
-
2022-01-31定向增发2500万美元未透露
-
2021-08-19IPO后其他轮次3000万美元未透露
-
2021-05-25上市未透露未透露
-
2017-12-04上市未透露未透露
- 加载更多
相关投融资企业
D轮
Circle Pharma is a biotechnology company focused on developing cell-permeable macrocyclic peptides against therapeutic targets using computational design and synthetic chemistry.In January 2016, Circle relocated to office and laboratory space in South San Francisco, CA.In June 2021, the company raised USD 66 million in an oversubscribed Series C financing.In March 2020, the company had raised USD 45 million in a series B financing round.In December 2016, the company issued USD 4.5 million shares of Series A preferred stock in a Series A financing round. In April 2017, the series A financing comprised of USD 6.5 million shares of series A preferred stock, was closed.In January 2016, the company extended its seed funding round with an investment from ShangPharma Investment Group
A轮
Gluetacs Therapeutics is a pharmaceutical company focused on protein degradation technology
增发
Foghorn Therapeutics Inc.成立于2015年10月。该公司率先发现并开发了一类针对染色质调节系统内基因决定依赖性的药物,这是一个尚未开发的治疗机会干预。该公司专有的基因流量控制平台为其提供了一个对染色质调节系统的各个组成部分如何相互作用的综合性、机械性理解,使其能够识别、验证系统内的潜在药物靶点。